Aegis capital corp. acted as sole bookrunner on a $2.6 million public offering of common stock for avenue therapeutics (nasdaq: atxi)

New york, ny / accesswire / november 12, 2021 / aegis capital corp. acted as sole bookrunner on a $2.6 million public offering of common stock for avenue therapeutics (nasdaq:atxi). about avenue therapeutics avenue therapeutics is a specialty pharmaceutical company whose mission is to develop iv tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the u.s. avenue is headquartered in new york city and was founded by fortress biotech, inc. (nasdaq:fbio).
ATXI Ratings Summary
ATXI Quant Ranking